Fig. 1
From: Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
Representative immunostaining of programmed death-ligand 1 (PD-L1), BRAF V600E mutation and EGFR 19del and L858R mutations (magnification, × 200). Anti-PD-L1 antibody (clone SP263) is validated using placenta as a positive control. HE staining of NPC tissue is presented in A. PD-L1 expression in NPC biopsy tissues was graded as 0% (b), 1–5% (c), 5–49% (d), and ≥ 50% (e and f). BRAF V600E and EGFR staining not shown